RHÖN-KLINIKUM Aktiengesellschaft (RHK) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of RHÖN-KLINIKUM Aktiengesellschaft stock €16.00, price €14.40, upside +11.1%, quality 59 out of 100. Rating: undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range €9.32 – €15.72 · fair‑value band €11.21 – €20.81 · the €14.40 price screens below the €16.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow RHÖN-KLINIKUM Aktiengesellschaft in your weekly email
Every Wednesday you see whether RHÖN-KLINIKUM Aktiengesellschaft is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
RHÖN-KLINIKUM, together with its subsidiaries, provides in-patient, semi-patient, and outpatient healthcare services in Germany. The company operates acute hospitals, medical care centers, and rehabilitation hospitals.
Show moreShow less
RHÖN-KLINIKUM was founded in 1973 and is based in Bad Neustadt an der Saale, Germany.
Stock analysis
RHÖN-KLINIKUM Aktiengesellschaft (RHK) currently trades at €14.40, while our model-based Fair Value estimate is €16.00, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €10.04 per share, and 2 of the 15 models we run sit above the €14.40 price.
Bear case: the Asset-Based group reads lowest at €5.85, and 13 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €11.21 (bear) to €20.81 (bull), the price of €14.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
RHÖN-KLINIKUM Aktiengesellschaft reported revenue of €1.9B in FY2025 versus €1.4B in FY2021, a compound +8.4%/yr. Reported net income was €34.5M in FY2025, compounding +5.1%/yr from FY2021.
Key figures
Market cap €930M Small · P/E ratio 22.5 · P/S ratio 0.46 · EPS (TTM) €0.6400 · Dividend yield 1.4% · Net margin 2.1% · Return on equity 3.3% · Return on assets (EBIT) 1.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 23% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 11%, RHK screens cheaper than that median.
Fair Value models
Bear€11.21Fair Value €16.00Bull€20.81
Price €14.40 · Upside +11.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.3761 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income€12.24€12.58€13.3576
EPV€1.15€1.18€1.2174
ROIC Compounder€1.15€1.18€1.2172
All 15 models by family
Earnings-Based
Graham-Dodd€3.50€7.38€9.3566
PEG = 1.0€1.11€1.59€2.0657
EPV€1.15€1.18€1.2174
Dividend Discount
Gordon GGM€0.7800€1.10€1.3969
DDM Multi-Stage€0.7800€1.05€1.3267
Multiples
P/E Multiple€8.50€11.33€14.1663
P/S Multiple€6.57€8.75€10.9458
P/B Multiple€13.20€17.60€22.0055
EV/EBIT€1.56€1.83€2.1166
EV/EBITDA€11.60€15.23€18.8667
EV/Revenue€1.32€1.57€1.8354
Asset-Based
NCAV (Graham)€3.86€5.85€7.3254
Economic Profit
Residual Income€12.24€12.58€13.3576
ROIC Compounder€1.15€1.18€1.2172
Growth Earnings
Growth-Adj P/E€6.23€8.89€11.5667
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+21.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic). Over 10 years: +5.7% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.0%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.0% vs −8.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 0%
News mood ⓘNews mood, the average tone of recent news (9 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare RHÖN-KLINIKUM Aktiengesellschaft with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside+11.1% · Above median
Profitability
Return on equity (12 months)3.3% · Below median
Return on assets1.9% · Below median
Net margin (12 months)2.1% · Below median
Operating margin (12 months)2.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)5.0% · Below median
Dividend yield (12 months)1.4% · Below median
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "RHÖN-KLINIKUM Aktiengesellschaft Fair Value". https://www.fairvalue-calculator.com/stock/RHK
Frequently asked questions
Is RHÖN-KLINIKUM Aktiengesellschaft (RHK) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €16.00 versus a price of €14.40, about +11% upside (undervalued).
What is the fair value of RHK?
Our model-based fair value for RHÖN-KLINIKUM Aktiengesellschaft is €16.00 (as of Nov 6, 2026), built from audited fundamentals. The current price: €14.40.
What is the quality score of RHK?
RHÖN-KLINIKUM Aktiengesellschaft has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Our model-based price target is the fair value of €16.00 (as of Nov 6, 2026) from 15 valuation models. Cautious scenario €11.21, optimistic scenario €20.81. It is a calculation from audited fundamentals, not an analyst target.
What is the RHÖN-KLINIKUM Aktiengesellschaft stock forecast for 2026?
Our models put fair value at €16.00, about +11% upside versus a price of €14.40 (undervalued). Cautious scenario €11.21, optimistic scenario €20.81. The calculation is refreshed regularly with new filings.
What is the revenue of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
RHÖN-KLINIKUM Aktiengesellschaft reported trailing-twelve-month revenue of about €2.0B (latest available figure, as of Nov 6, 2026).
Does RHÖN-KLINIKUM Aktiengesellschaft pay a dividend?
RHÖN-KLINIKUM Aktiengesellschaft currently shows a dividend yield of 1.39% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of RHÖN-KLINIKUM Aktiengesellschaft (RHK) and when is the ex-dividend date?
RHÖN-KLINIKUM Aktiengesellschaft pays a dividend of €0.2 per share a year, a dividend yield of 1.4%. The last ex-dividend date was May 28, 2026. The payout ratio is 31.3% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RHÖN-KLINIKUM Aktiengesellschaft it is €16.00 per share (as of Nov 6, 2026), against a price of €14.40. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is RHÖN-KLINIKUM Aktiengesellschaft stock overvalued or undervalued in 2026?
As of Nov 6, 2026, RHK trades below its calculated fair value: price €14.40, fair value €16.00, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RHK?
No. The price is what the market pays today (€14.40); the fair value is what the company's own numbers justify (€16.00). For RHÖN-KLINIKUM Aktiengesellschaft the two are €1.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is RHÖN-KLINIKUM Aktiengesellschaft worth?
The market values RHÖN-KLINIKUM Aktiengesellschaft at about €930M (market capitalisation, as of Nov 6, 2026). Per share that is €14.40; our models calculate a fair value of €16.00 per share.
What do the bullish and bearish scenarios say about RHK?
Our models span a range for RHÖN-KLINIKUM Aktiengesellschaft: cautious scenario €11.21, base €16.00, optimistic €20.81 per share (as of Nov 6, 2026, price €14.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RHK?
RHÖN-KLINIKUM Aktiengesellschaft trades at a price-to-earnings ratio of 22.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €16.00 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 30.3. Other multiples: PEG 4.0, P/B 0.7, P/S 0.5, EV/EBITDA 7.8.
What is the PEG ratio of RHK?
The PEG ratio of RHÖN-KLINIKUM Aktiengesellschaft is 4.01 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Balance-sheet figures for RHÖN-KLINIKUM Aktiengesellschaft (as of Nov 6, 2026): return on equity 3.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is RHK from its 52-week high?
RHÖN-KLINIKUM Aktiengesellschaft trades at €14.40, about 4% below its 52-week high of €15.00 and 23% above the low of €11.71 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €16.00 is for.
Which stocks are comparable to RHÖN-KLINIKUM Aktiengesellschaft?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RHÖN-KLINIKUM Aktiengesellschaft stock attractive at the current price?
The data as of Nov 6, 2026: price €14.40, calculated fair value €16.00 (+11%), Quality Score 59/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RHK calculated?
We run RHÖN-KLINIKUM Aktiengesellschaft through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €16.00 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. RHÖN-KLINIKUM Aktiengesellschaft currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The closing price on Nov 6, 2026 was €14.40. Our model-based fair value is €16.00, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RHÖN-KLINIKUM Aktiengesellschaft right now?
A fairly wide model range (€11.21 to €20.81) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of RHÖN-KLINIKUM Aktiengesellschaft (RHK) come from?
Earnings per share at RHÖN-KLINIKUM Aktiengesellschaft grew −21.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.2 %, EBIT margin −29.3 %, tax rate −2.1 %, residual (interest, one-offs) +6.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of RHÖN-KLINIKUM Aktiengesellschaft
How large is the market capitalisation of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The market capitalisation of RHÖN-KLINIKUM Aktiengesellschaft is €930M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The price-to-sales ratio of RHÖN-KLINIKUM Aktiengesellschaft is 0.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Earnings per share at RHÖN-KLINIKUM Aktiengesellschaft are €0.6400 (price ÷ EPS = P/E 22.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The dividend yield of RHÖN-KLINIKUM Aktiengesellschaft is 1.4% (payout 31.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The net margin of RHÖN-KLINIKUM Aktiengesellschaft is 2.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The return on equity (ROE) of RHÖN-KLINIKUM Aktiengesellschaft is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
On an EBIT basis the return on assets of RHÖN-KLINIKUM Aktiengesellschaft is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
The operating margin of RHÖN-KLINIKUM Aktiengesellschaft is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Revenue at RHÖN-KLINIKUM Aktiengesellschaft is growing +5.0% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RHÖN-KLINIKUM Aktiengesellschaft (RHK)?
Earnings per share at RHÖN-KLINIKUM Aktiengesellschaft are growing +40.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does RHÖN-KLINIKUM Aktiengesellschaft (RHK) generate?
The free cash flow of RHÖN-KLINIKUM Aktiengesellschaft is −€34.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does RHÖN-KLINIKUM Aktiengesellschaft (RHK) hold?
RHÖN-KLINIKUM Aktiengesellschaft holds more cash than debt, €48.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch RHÖN-KLINIKUM Aktiengesellschaft in the live analysis
One click puts RHÖN-KLINIKUM Aktiengesellschaft on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026